Mushrooms are a good treatment for chronic cluster headache.
Capsule: Psilocybin, lysergic acid diethylamide, and related psychedelic trIptamines were reportedly effective for both preventive and acute treatment of cluster headache, but is there scientific evidence to recommend it to our patients?
08:30-08:40
Host: Dimos Mitsikostas, Greece
08:40-08:55
Yes: Brian E. McGeeney, USA
08:55-09:10
No: Randall Weeks, USA
09:10-09:20
Discussion and rebuttals
09:20-10:10
Acupuncture is at least as effective as migraine prophylactic drugs, but with fewer unwanted side effects.
Capsule: In recent years the evidence base for acupuncture as a prophylactic treatment for headache has grown considerably due to the publication of several large trials of high quality, but the results are still challenging and not easy to interpret.
09:20-09:30
Host: Jose Miguel Lainez, Spain
09:30-09:45
Yes: Min Kyung Chu, South Korea
09:45-10:00
No:
10:00-10:10
Discussion and rebuttals
10:10-10:25
Coffee Break
10:25-12:05
SECTION TITLE
10:25-11:10
Head injury can precipitate the onset of migraine.
Capsule: Post-traumatic headache may be nonspecific in character and may have a symptom pattern indistinguishable from other non-traumatic headache syndromes such as migraine with or without aura.
10:25-10:35
Host: Manjit Matharu, UK
10:35-10:50
Yes: Oved Daniel, Israel
10:50-11:05
No: Mark Braschinsky, Estonia
11:05-11:10
Discussion and rebuttals
11:10-12:05
Estrogen containing contraceptives are safe in women with migraine with aura.
Capsule: Migraine with aura has been associated with increased risk of ischemic and hemorrhagic stroke. Prior studies have shown a further increase in risk in women using combined hormonal contraceptives (CHCs). This has led to guidelines recommending against use of CHCs in this population. Recent data shows a lack of good quality studies assessing risk of stroke associated with low dose estrogen use in women with migraine.
11:10-11:20
Host: Pooja Dassan, UK
11:20-11:35
Yes: Anne MacGregor, UK
11:35-11:50
No: Chris Gottschalk, USA
11:50-11:55
Discussion and rebuttals
11:55-12:15
How are the CGRP monoclonal antibodies being used today?Chris Gottschalk, USA
12:15-13:15
Industry Supported Symposium
13:15-14:15
Lunch Break
13:15-14:15
Meet the Expert
14:15-15:45
SECTION TITLE
14:15-14:55
Peripheral trigeminal structures are the primary interaction site for CGRP antagonism in migraine prevention
Capsule: CGRP plays a crucial role in migraine pathophysiology. Monoclonal antibodies to CGRP or its receptor will replace tradition preventive therapies form migraine.
14:15-14:25
Host: Fayyaz Ahmed, UK
14:25-14:35
Yes: Lars Edvinsson, Sweden
14:35-14:45
No: Dimos Mitsikostas, Greece
14:45-14:55
Discussion and rebuttals
14:55-15:45
Vestibular migraine – does it exist?
Capsule: Vestibular migraine is a term used to describe episodic vertigo in migraine patients, but is it a distinct diagnosis, or simply a sensory manifestation of migraine?
14:55-15:05
Host: Min Kyung Chu, South Korea
15:05-15:20
Yes: Christian Lampl, Austria
15:20-15:35
No: Jack Schim, USA
15:35-15:45
Discussion and rebuttals
15:45-16:00
Coffee Break
16:00-19:00
SECTION TITLE
16:00-16:50
Correcting the derangement in sleep architecture is sufficient to treat cluster and migraine headache without medication.
Capsule: Migraineurs and cluster headache patients who do not sleep well develop more frequent and severe headaches. Would optimal sleep therapies ever be good enough to take the place of medication for the treatment of these headaches, or is sleep impairment just an epiphenomenon?
16:00-16:10
Host: Jack Schim, USA
16:10-16:25
Yes: Bojana Zvan, Slovenia
16:25-16:40
No: Oved Daniel, Israel
16:40-16:50
Discussion and rebuttals
16:50-17:40
Devices will replace medications for the treatment of headache.
Capsule: Medical devices are a rapidly growing field in the headache disorders provides an alternative therapeutic option particularly for Migraine and Cluster Headache.
16:50-17:00
Host: Anna Anrdreou, UK
17:00-17:15
Yes: Jose Miguel Lainez, Spain
17:15-17:30
No: Giorgio Lambru, UK
17:30-17:40
Discussion and rebuttals
17:40-18:30
The safety and efficacy of CGRP mAbs are known enough to recommend them for long-term use.
17:40-17:50
Host: Giorgio Lambru, UK
17:50-18:05
Yes: Lars Edvinsson, Sweden
18:05-18:20
No: Fayyaz Ahmed, UK
18:20-18:30
Discussion and rebuttals
18:30-19:00
The changing face of medication-overuse headache Alan Rapoport, USA